BeOne Medicines AG/$ONC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BeOne Medicines AG
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Ticker
$ONC
Sector
Primary listing
Employees
11,000
Headquarters
Basel, Switzerland
Website
ONC Metrics
BasicAdvanced
$39B
602.40
$0.58
0.46
-
Price and volume
Market cap
$39B
Beta
0.46
52-week high
$385.22
52-week low
$196.45
Average daily volume
235K
Financial strength
Current ratio
2.392
Quick ratio
2.085
Long term debt to equity
4.624
Total debt to equity
24.701
Interest coverage (TTM)
6.93%
Profitability
EBITDA (TTM)
328.171
Gross margin (TTM)
86.19%
Net profit margin (TTM)
1.38%
Operating margin (TTM)
3.66%
Effective tax rate (TTM)
62.39%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
1.69%
Return on equity (TTM)
1.81%
Valuation
Price to earnings (TTM)
602.4
Price to revenue (TTM)
7.659
Price to book
9.45
Price to tangible book (TTM)
9.6
Price to free cash flow (TTM)
82.101
Free cash flow yield (TTM)
1.22%
Free cash flow per share (TTM)
4.29
Growth
Revenue change (TTM)
50.43%
Earnings per share change (TTM)
-107.43%
3-year revenue growth (CAGR)
58.46%
10-year revenue growth (CAGR)
97.45%
3-year earnings per share growth (CAGR)
-69.83%
10-year earnings per share growth (CAGR)
-17.63%
ONC News
AllArticlesVideos
BeOne Medicines to Present at Upcoming Investor Conferences
Business Wire·1 week ago
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
Business Wire·2 weeks ago
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeOne Medicines AG stock?
BeOne Medicines AG (ONC) has a market cap of $39B as of February 26, 2026.
What is the P/E ratio for BeOne Medicines AG stock?
The price to earnings (P/E) ratio for BeOne Medicines AG (ONC) stock is 602.4 as of February 26, 2026.
Does BeOne Medicines AG stock pay dividends?
No, BeOne Medicines AG (ONC) stock does not pay dividends to its shareholders as of February 26, 2026.
When is the next BeOne Medicines AG dividend payment date?
BeOne Medicines AG (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeOne Medicines AG?
BeOne Medicines AG (ONC) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.